- Home
- AXS vs ROIV Comparison
AXS vs ROIV Comparison
Compare AXS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AXS | ROIV |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | Bermuda | United Kingdom |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AXS | ROIV |
|---|---|---|
| Price | $103.27 | $21.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $117.88 | $24.31 |
| AVG Volume (30 Days) | 572.2K | ★ 8.3M |
| Earning Date | 01-28-2026 | 02-09-2026 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | ★ 68.27 | N/A |
| EPS | ★ 12.10 | N/A |
| Revenue | ★ $6,301,015,000.00 | $20,329,000.00 |
| Revenue This Year | $6.62 | N/A |
| Revenue Next Year | $8.61 | $741.42 |
| P/E Ratio | $8.52 | ★ N/A |
| Revenue Growth | ★ 5.59 | N/A |
| 52 Week Low | $83.90 | $8.73 |
| 52 Week High | $110.34 | $23.47 |
Technical Indicators
Market Signals| Indicator | AXS | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 54.28 |
| Support Level | $105.67 | $20.78 |
| Resistance Level | $109.57 | $22.21 |
| Average True Range (ATR) | 1.70 | 0.66 |
| MACD | -0.84 | -0.15 |
| Stochastic Oscillator | 12.62 | 40.50 |
Price Performance
Historical ComparisonAbout AXS Axis Capital Holdings Limited
Axis Capital Holdings Ltd is a specialty underwriter and provider of insurance and reinsurance solutions with operations in Bermuda, the United States ("U.S."), Europe, Singapore, and Canada. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks. The company's segment consists of AXIS Insurance and AXIS Reinsurance. The company generates the majority of its revenue from the Insurance segment. Geographically, the company generates the majority of its revenue from the United States.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.